Amgen files sBLA for XGEVA
The company’s sBLA is supported by the results of a Phase 3 Study (‘147) investigating XGEVA versus placebo in 1,432 men with castrate-resistant prostate cancer. The results of
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.